Acute Myelogenous Leukemia: Clinical Trials

99 trials for Acute Myelogenous Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

55 completed, 27 terminated, 7 unknown, 4 withdrawn. 99 Phase 1, 40 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 199Completed 55, Terminated 27, Unknown 7, Withdrawn 4, Active not recruiting 3, Recruiting 2, Suspended 1
Phase 240Completed 20, Terminated 9, Unknown 5, Active not recruiting 2, Withdrawn 2, Recruiting 1, Suspended 1

Follow Acute Myelogenous Leukemia: new trials by email Literature Review of Acute Myelogenous Leukemia trials Research Report on Acute Myelogenous Leukemia

Trials (filtered) newest first · largest first

All 99 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
AdaptNK, Fludarabine, Cyclophosphamide - Relapsed Adult AML, Refractory AML
Phase 1 / Phase 2RecruitingMasonic Cancer Center, University of Minnesota182026-05-082026-05-19
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
ICP-248, Azacitidine - Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
Phase 1RecruitingBeijing InnoCare Pharma Tech Co., Ltd.2662024-12-182026-08-18
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells, Dendritic Cell Vaccine - Refractory Leukemia, Relapsed Leukemia
Phase 1WithdrawnJuan C. Ramos, MD2023-11-302023-12-04
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
TBX-2400 - Myelofibrosis, Acute Myelogenous Leukemia
Phase 1UnknownTaiga Biotechnologies, Inc.102022-09-012022-05-03
Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Gentulizumab - Acute Myelogenous Leukemia, Myelodysplastic Syndromes
Phase 1TerminatedChangchun GeneScience Pharmaceutical Co., Ltd.582021-04-012026-04-06
A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia
SH1573 Capsules - Acute Myelogenous Leukemia
Phase 1UnknownNanjing Sanhome Pharmaceutical, Co., Ltd.412020-08-042021-03-19
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Emavusertib, Venetoclax - Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Phase 1 / Phase 2SuspendedCuris, Inc.3662020-07-062026-03-19
Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia
Azacitidine, Venetoclax, Pevonedistat - Acute Myelogenous Leukemia
Phase 1TerminatedMedical College of Wisconsin162020-01-132024-06-04
Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia
CD33CART autologous, CD33CART allogeneic - Acute Myelogenous Leukemia
Phase 1 / Phase 2Active not recruitingCenter for International Blood and Marrow Transplant Research522020-01-082025-07-14
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
GTB-3550 TriKE® Phase I, GTB-3550 TriKE® Phase II - High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia
Phase 1 / Phase 2TerminatedGT Biopharma, Inc.122020-01-012022-11-10
FT516 in Subjects With Advanced Hematologic Malignancies
FT516, Rituximab, Obinutuzumab - Acute Myelogenous Leukemia, B-cell Lymphoma
Phase 1TerminatedFate Therapeutics722019-10-042023-10-26
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
galinpepimut-S, pembrolizumab, Montanide - Acute Myelogenous Leukemia, Ovarian Cancer
Phase 1 / Phase 2CompletedSellas Life Sciences Group262019-09-302024-11-19
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Stem cell transplantation, Itacitinib, Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Phase 1CompletedWashington University School of Medicine552019-09-042025-04-06
CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myelogenous Leukemia
Phase 1TerminatedJonsson Comprehensive Cancer Center132019-07-182023-11-18
Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients
DC/AML fusion cells - Acute Myelogenous Leukemia
Phase 1Active not recruitingBeth Israel Deaconess Medical Center282018-10-112026-09-29
Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS
Pevonedistat, Cytarabine - Acute Myelogenous Leukemia, AML
Phase 1CompletedJustin Watts, MD122018-05-212021-12-28
Epigenetic Reprogramming in Relapse/Refractory AML
Decitabine, Vorinostat, Filgrastim (G-CSF) - Acute Myelogenous Leukemia
Phase 1CompletedTherapeutic Advances in Childhood Leukemia Consortium372017-07-112025-10-16
Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)
Ciprofloxacin 750 MG, Etoposide, Ciprofloxacin 1000 MG - Leukemia, Acute Myelogenous Leukemia
Phase 1 / Phase 2TerminatedUniversity of Florida112016-12-162022-08-05
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Bendamustine, Cyclophosphamide - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Phase 1CompletedUniversity of Arizona502016-11-292025-11-10
CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML
anti-CD33 CAR-NK cells - Acute Myelogenous Leukemia, Acute Myeloid Leukemia
Phase 1 / Phase 2UnknownPersonGen BioTherapeutics (Suzhou) Co., Ltd.102016-10-012016-12-06

Showing 20 of 99. Sign in to see all of them.

Narrower conditions

Leukemia, Myeloid, Acute (99)  ·  Myelodysplastic Syndromes (36)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (24)  ·  Leukemia (16)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (14)  ·  Recurrence (10)  ·  Lymphoma, Non-Hodgkin (8)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (7)  ·  Hodgkin Disease (5)  ·  Lymphoma (5)  ·  Multiple Myeloma (4)  ·  Primary Myelofibrosis (4)  ·  Burkitt Lymphoma (3)  ·  Leukemia, Myeloid (3)  ·  Anemia, Refractory, with Excess of Blasts (2)

Broader conditions

Hemic and Lymphatic Diseases (99)  ·  Neoplasms by Histologic Type (99)  ·  Hematologic Diseases (98)  ·  Neoplasms (97)  ·  Leukemia, Myeloid (96)  ·  Leukemia (83)  ·  Bone Marrow Diseases (44)  ·  Immune System Diseases (31)  ·  Immunoproliferative Disorders (30)  ·  Lymphatic Diseases (30)  ·  Lymphoproliferative Disorders (29)  ·  Disease Attributes (27)  ·  Pathologic Processes (27)  ·  Pathological Conditions, Signs and Symptoms (27)  ·  Leukemia, Lymphoid (26)

Interventions

Cytarabine (15)  ·  Azacitidine (11)  ·  Cyclophosphamide (7)  ·  fludarabine (7)  ·  fludarabine phosphate (6)  ·  Clofarabine (5)  ·  Etoposide (4)  ·  Tretinoin (4)  ·  pevonedistat (4)  ·  venetoclax (4)  ·  Busulfan (3)  ·  Decitabine (3)  ·  Gemtuzumab (3)  ·  Interleukin-2 (3)  ·  Lenalidomide (3)

Sponsors

M.D. Anderson Cancer Center (7)  ·  Masonic Cancer Center, University of Minnesota (5)  ·  Massachusetts General Hospital (5)  ·  Millennium Pharmaceuticals, Inc. (5)  ·  Genzyme, a Sanofi Company (3)  ·  New York Medical College (3)  ·  AbbVie (2)  ·  Abramson Cancer Center at Penn Medicine (2)  ·  Forma Therapeutics, Inc. (2)  ·  Seagen Inc. (2)  ·  University of Bergen (2)  ·  AbbVie (prior sponsor, Abbott) (1)  ·  Aptose Biosciences Inc. (1)  ·  Asan Medical Center (1)  ·  AstraZeneca (1)

Countries

United States (84)  ·  Australia (5)  ·  France (5)  ·  Germany (5)  ·  Italy (5)  ·  Canada (4)  ·  China (4)  ·  Belgium (2)  ·  Japan (2)  ·  Norway (2)  ·  South Korea (2)  ·  Spain (2)  ·  Croatia (1)  ·  Czechia (1)  ·  Israel (1)

Top investigators

Amir Fathi, MD (3)  ·  Justin Watts, MD (2)  ·  Oystein Bruserud, MD (2)  ·  Andrea Bacigalupo, MD (1)  ·  Anna R Franklin, MD (1)  ·  Anthony S Stein, MD (1)  ·  Barry J Maurer, MD, PhD (1)  ·  Brigitte C Widemann, M.D. (1)  ·  Caspian Oliai, MD (1)  ·  Daniel J. DeAngelo, MD, PhD (1)

Results publications

PMID 28877686, PMID 31355467, PMID 33917201, PMID 35829925, PMID 18922099, PMID 19007987, PMID 19029442, PMID 21060028, PMID 21494838, PMID 21967976, PMID 22829110, PMID 24075534, PMID 24794806, PMID 25682597, PMID 25733005, PMID 25933833, PMID 27931243, PMID 28034990, PMID 28054442, PMID 28161120, PMID 28939558, PMID 29196412, PMID 29339097, PMID 29348128, PMID 29908231, PMID 30361262, PMID 31092732, PMID 31266741, PMID 31551349, PMID 31860140, PMID 32582591, PMID 33208914, PMID 33495312, PMID 33666654, PMID 34152898, PMID 34531250, PMID 34839054, PMID 35046058, PMID 35063965, PMID 35460929, PMID 35579731, PMID 35847727, PMID 36007102, PMID 36226495, PMID 36370742, PMID 36724515, PMID 37647601, PMID 38091578, PMID 38572562, PMID 38841781

NIH funding

2014 (2), 2015 (1), K12CA167540 (1), P50CA206963 (1), R01HL114591 (1), R21CA143805 (1)